Obesity is one of the most common health issues in the world, which also triggers other diseases.Prolonged obesity can ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

Many patients taking obesity and diabetes drugs like Ozempic and Wegovy have found its benefits go beyond weight loss.

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and ...

Arrowhead Pharmaceutical’s investigational RNA interference (RNAi) obesity candidate in combination with Eli Lilly’s Zepbound ...

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

Pharma giant AbbVie reveals plans to expand its presence in the obesity drug market through pipeline development and ...

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...